Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd (EMCURE) last traded at ₹1,854, a market capitalisation of ₹35,166 crore, on a P/E of 34.1. Over the past 52 weeks the stock has ranged between ₹1,260 and ₹2,048. Emcure Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹2,580 crore and net profit of ₹292 crore. Emcure Pharmaceuticals Ltd’s annual general meeting is scheduled for 21 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Emcure Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Emcure Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,580 cr, up 22.8% from ₹2,101 cr a year earlier. Net profit was ₹292 cr, up 35.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Expenses | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 |
| Operating profit | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 |
| OPM % | 19% | 18% | 19% | 20% | 21% | 21% | 19% | 21% |
| Other income | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 |
| Interest | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 |
| Depreciation | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 |
| Profit before tax | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 |
| Tax % | 26% | 32% | 24% | 26% | 26% | 26% | 29% | 26% |
| Net profit | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| EPS (₹) | 10.29 | 8.11 | 9.97 | 10.92 | 12.84 | 12.16 | 12.84 | 15.50 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Emcure Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 9,204 | 9,683 |
| Operating profit | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,865 | 1,980 |
| OPM % | 24% | 23% | 20% | 18% | 19% | 20% | 20% |
| Net profit | 419 | 703 | 562 | 528 | 707 | 941 | 1,019 |
| EPS (₹) | 23.15 | 36.62 | 29.42 | 27.50 | 35.96 | 48.76 | 53.34 |
TTM is the trailing twelve months to the most recent quarter.
Emcure Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 15%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 21%
- TTM
- 37%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 24%
- 10 Years
- %
- 5 Years
- 22%
- 3 Years
- 19%
- Last Year
- 20%
Emcure Pharmaceuticals Ltd shareholding pattern
Promoters held 77.83% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.87% and DIIs 8.46%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 78.08% | 77.94% | 77.92% | 77.92% | 77.88% | 77.87% | 77.87% | 77.83% |
| FIIs | 2.91% | 3.05% | 3.06% | 2.86% | 3.29% | 3.59% | 3.35% | 4.87% |
| DIIs | 3.96% | 3.87% | 3.44% | 2.84% | 4.36% | 6.10% | 6.10% | 8.46% |
| Public | 15.05% | 15.15% | 15.58% | 16.39% | 14.46% | 12.43% | 12.69% | 8.84% |
| No. of shareholders | 1,52,914 | 1,43,449 | 1,39,671 | 1,33,549 | 1,26,169 | 1,18,863 | 1,22,189 | 1,24,991 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Emcure Pharmaceuticals Ltd’s AGM?
Emcure Pharmaceuticals Ltd’s annual general meeting is scheduled for 21 Sept 2026.
- AGMBoard composition changes including retirement of Chairman and appointment of new Independent Director
See the full results calendar for every Indian company reporting in the next 30 days.
Emcure Pharmaceuticals Ltd corporate filings
- Allotment of 19,100 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 2013Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has allotted 19,100 equity shares to employees following the…
Read the full analysis - Transcript of Earnings Call - Q1 FY27Company Updatehigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited delivered a robust Q1 FY27 performance, with revenue from…
Read the full analysis - Update on USFDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, IndiaCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has issued a regulatory intimation regarding a USFDA inspection at…
Read the full analysis - Analyst/ Investor Meet on Tuesday, September 22, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Analyst/ Investor Meet on Thursday, September 17, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Analyst/ Investor Meet on Tuesday, September 01, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Analyst/ Investor Meet on Tuesday, August 18, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Analyst/Investor Meet on Wednesday, August 12, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has released its unaudited consolidated financial results…
Read the full analysis - Audio recording of Earnings Call - Q1 FY27Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has formally filed the audio recording of its Q1 FY27…
Read the full analysis - Intimation of date of the 45th Annual General Meeting and Record Date for payment of Final Dividend on Equity Shares for the Financial Year March 31, 2026Corp. Actionlow impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has scheduled its 45th Annual General Meeting for…
Read the full analysis - Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Change in composition of the Board of the CompanyCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has announced a significant change in its board…
Read the full analysis - Presentation on Unaudited Financial Results for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited delivered a robust performance for Q1 FY27, reporting…
Read the full analysis - Unaudited Financial Results (Standalone and consolidated) for the quarter ended June 30, 2026Resulthigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited delivered a robust performance for the quarter ended June…
Read the full analysis - Outcome of Board Meeting held on August 06, 2026Board Meetinghigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited delivered a robust performance for the quarter ended June…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Emcure Pharmaceuticals Ltd
Cruxal reads every Emcure Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.